Get the Stockscreener App
739.16
1.55%
-10.95
Regeneron Pharmaceuticals Inc stock is traded at $739.16, with a volume of 225.85K.
It is down -1.55% in the last 24 hours and up +13.30% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$750.11
Open:
$742.12
24h Volume:
225.85K
Relative Volume:
0.21
Market Cap:
$76.28B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
17.70
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
-6.20%
1M Performance:
+13.30%
6M Performance:
+50.47%
1Y Performance:
-3.13%
1-Day Range:
$731.00
$747.00
1-Week Range:
$731.00
$790.98
52-Week Range:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
738.53 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.00 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
468.27 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.16 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
210.29 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Sepio Capital LP Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What Wall Street predicts for Regeneron Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & AI Enhanced Trading Signals - Newser
Quadrant Capital Group LLC Sells 688 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Distillate Capital Partners LLC Has $14.69 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN): Is There More Value Ahead After Recent Uptrend? - simplywall.st
Can Regeneron Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Institutional & High Accuracy Buy Signal Tips - Newser
Will Regeneron Pharmaceuticals Inc. (RGO) stock benefit from sector leadershipNew Guidance & Smart Allocation Stock Reports - Newser
Tessera Will Team With Regeneron On Gene-Writing Therapy For AATD - Citeline News & Insights
Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder - MedCity News
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron (REGN) Invests $150M in Tessera's Gene Editing Therapy - GuruFocus
Regeneron inks deal with Tessera to develop gene editing therapy - Seeking Alpha
Regeneron and Tessera advance TSRA-196 toward IND/CTA filings - CRISPR Medicine News
Regeneron and Tessera join forces to forge in vivo AATD gene therapy - Yahoo Finance
Somerville biotech secures $150M upfront from Regeneron for gene-editing treatment - The Business Journals
Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder - Benzinga
Regeneron inks gene editing deal with startup Tessera - BioPharma Dive
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing - Finviz
Regeneron and Tessera collaborate on TSRA-196 - BioWorld MedTech
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Yahoo Finance
Regeneron, Tessera Therapeutics Partner to Develop & Commercialize TSRA-196 - Contract Pharma
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD - BioSpace
Regeneron and Tessera Therapeutics to jointly develop TSRA-196 - MarketScreener
Regeneron and Tessera partner on gene therapy for alpha-1 deficiency - Investing.com Australia
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by New York State Common Retirement Fund - MarketBeat
Regeneron (REGN) Partners with Tessera to Advance Gene Therapy f - GuruFocus
Regeneron, Tessera Enter Collaboration To Develop TSRA-196 - Nasdaq
Regeneron (NASDAQ:REGN) in $150M Tessera pact on TSRA-196 AATD gene therapy - Stock Titan
Norges Bank Invests $628.15 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Inceptionr LLC Invests $328,000 in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Global Retirement Partners LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? - The Globe and Mail
Virtus Investment Advisers LLC Acquires 366 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Virtue Capital Management LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
State Board of Administration of Florida Retirement System Has $54.71 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Korea Investment CORP Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Steward Partners Investment Advisory LLC Has $2.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Loomis Sayles & Co. L P Acquires 305,089 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Quadrature Capital Ltd Takes $36.97 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Groupama Asset Managment Sells 22,742 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Has $34.27 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Johnson Financial Group Inc. Purchases 327 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Vinva Investment Management Ltd - MarketBeat
Choreo LLC Acquires 1,224 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Earnings Beat: What is the fair value of Regeneron Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Short-Term Swing Trade Alerts - BỘ NỘI VỤ
Advisors Asset Management Inc. Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Will EU Approval of Dupixent for CSU Transform Regeneron Pharmaceuticals' (REGN) Long-Term Growth Narrative? - simplywall.st
Regeneron Claims Biocon Drug Mimics Its Patented Medicine - Law360
Te Ahumairangi Investment Management Ltd Acquires 4,278 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Russell Investments Group Ltd. Has $91.14 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? - Barchart.com
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):